Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,809 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05961111RecruitingEarly Phase 1
Oncolytic virus injection for advanced solid tumors
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
Linyi, ShandongAges 18–75 - NCT05970666RecruitingPhase 2
TACE plus immunotherapy and VEGF drug for unresectable liver cancer
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Xiamen, FujianAges 18–75 - NCT05989542RecruitingPhase 3
Study of vebreltinib for MET-mutated lung cancer
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT05995054RecruitingPhase 2
Obinutuzumab for chronic ITP that hasn't responded to steroids
This trial tests a drug called obinutuzumab for people with chronic ITP (low platelets) who haven't gotten better with steroids. The goal is to see if it can safely raise your platelet count.
TianjinAges 18 years+ - NCT05998928RecruitingPhase 2
BCMA-GPRC5D CAR-T for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06001086RecruitingPhase 2
Disitamab Vedotin plus Pyrotinib for HER2-positive early breast cancer
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
Nanjing, JiangsuAges 18 years+ - NCT06001918RecruitingPhase 2/Phase 3
Testing a new aneurysm treatment device
This trial tests a new device (Nectero EAST) for treating abdominal aortic aneurysms without major surgery. It may be an option for people with a medium-size aneurysm who have not had prior repair.
Scottsdale, ArizonaAges 21–85 - NCT06008925RecruitingPhase 1/Phase 2
VG161 plus nivolumab for advanced gastric cancer
This trial tests a new combination therapy (VG161, a herpes-based virus therapy, plus nivolumab) for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two previous treatments, including a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT06010862RecruitingPhase 1
CAR-T therapy for CEA-positive advanced cancers
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
Nanchang, JiangxiAges 18 years+ - NCT06013111RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new treatment called Anti-CEA-CAR-T cells, which are specially modified immune cells that target a protein called CEA found on certain cancer cells. It is for people with advanced solid tumors, especially digestive system cancers, that have not responded to other treatments.
Shenyang, LiaoningAges 18–70 - NCT06019702RecruitingPhase 1
Personalized mRNA vaccine for advanced digestive cancers
This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.
Hangzhou, ZhejiangAges 18–75 - NCT06026774RecruitingPhase 1
Personalized mRNA Vaccine After Digestive Cancer Surgery
This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.
Hangzhou, ZhejiangAges 18–75 - NCT06026800RecruitingPhase 1
Personalized mRNA vaccine plus standard treatment for advanced digestive cancers
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
Hangzhou, ZhejiangAges 18–75 - NCT06077942Recruiting
FX shoulder replacement study
This study looks at how well FX shoulder replacement devices work for people who received them between 2018 and 2023. It helps doctors learn more about the outcomes of these implants.
Gilbert, ArizonaAges Any age - NCT06078865Recruiting
FX Shoulder Replacement Study
This study follows people who receive an FX shoulder replacement device to see how it works over time. It may be a good fit if you are planning this specific surgery with your doctor.
Gilbert, ArizonaAges Any age - NCT06084819RecruitingPhase 2
New drug combo for relapsed AML
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
Beijing, Beijing MunicipalityAges 14–75 - NCT06088745RecruitingPhase 3
Shingles vaccine trial for adults 40+
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
Zhenjiang, JiangsuAges 40 years+ - NCT06091774Recruiting
Digital therapy for heart disease risk factors
This study tests a smartphone app (iATROS) for managing heart disease risk factors in patients with coronary heart disease. If you have had a heart attack, a stent, angioplasty, or bypass surgery, and you can use a smartphone, this program may help you reduce your risk through digital monitoring and guidance.
Munich, BavariaAges 18 years+ - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT06106906RecruitingPhase 1/Phase 2
CD19 CAR-T for Active Lupus
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
Wuhan, HubeiAges 18–70 - NCT06106893RecruitingPhase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
Wuhan, HubeiAges 18–70 - NCT06117735Recruiting
Covered stent for portal hypertension
This trial tests a special stent to treat high blood pressure in the liver caused by cirrhosis. It may help patients who need a procedure called TIPS to improve blood flow.
Fuzhou, FujianAges 18–85 - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,809 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.